Conceptual Background and Bioenergetic/mitochondrial Aspects of Oncometabolism

Front Cover
Elsevier, 2014 - HEALTH & FITNESS - 509 pages
0 Reviews
Volume 542 of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This new volume covers research methods providing a theoretical overview on metabolic alterations of cancer cells and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo. Malignant cells exhibit metabolic changes when compared to their normal counterparts, owing to both genetic and epigenetic alterations. Although such a metabolic rewiring has recently been indicated as "yet another" general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm rather represent a molecular signature that intimately accompanies, and hence cannot be severed from, all facets of malignant transformation.

  • Continues the legacy of this premier serial with quality chapters authored by leaders in the field
  • Covers research methods in biomineralization science
  • Provides theoretical overview on metabolic alterations of cancer cells, and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo

What people are saying - Write a review

We haven't found any reviews in the usual places.

Other editions - View all

About the author (2014)

Lorenzo Galluzzi received his Ph.D. in 2008 from the University of Paris Sud/Paris XI (France), and now works as a research manager in the laboratory of Guido Kroemer. He is particularly fascinated by several aspects of mitochondrial cell death, autophagy, cancer cell metabolism and tumour immunology. He has published more than 270 articles in peer-reviewed scientific journals, and is currently the 6th and youngest of the 30 most-cited European cell biologists (relative to the period 2007-2013).

Guido Kroemer got his M.D. in 1985 from the University of Innsbruck, Austria, and his Ph.D. in molecular biology in 1992 from the Autonomous University of Madrid, Spain. He is currently Professor at the Faculty of Medicine of the University of Paris Descartes/Paris V, Director of the INSERM research team 'Apoptosis, Cancer and Immunity', Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Cancer Campus, and Practitioner at the H pital Europ en George Pompidou (Paris, France). He is also the Director of the Paris Alliance of Cancer Research Institutes (PACRI) and the Labex 'Immuno-Oncology'. Dr. Kroemer is best known for the discoveries that mitochondrial membrane permeabilization constitutes a decisive step in regulated cell death; that autophagy is a cytoprotective mechanism with lifespan-extending effects; and that anticancer therapies are successful only if they stimulate tumour-targeting immune responses. He is currently the most-cited cell biologist in Europe (relative to the period 2007-2013), and he has received the Descartes Prize of the European Union, the Carus Medal of the Leopoldina, the Dautrebande Prize of the Belgian Royal Academy of Medicine, the L opold Griffuel Prize of the French Association for Cancer Research, the Mitjavile prize of the French National Academy of Medicine and a European Research Council Advanced Investigator Award.

Bibliographic information